Prices are updated after-hours
Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Positive    crawled time : 20:20    save search
Celldex Therapeutics Presents Positive 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria
Published: 2024-02-24 (Crawled : 20:20) - globenewswire.com
CLDX | $39.01 -0.15% 27K twitter stocktwits trandingview |
Health Technology
 | Email alert Add to watchlist
urticaria positive week therapeutics results study
Poseida Therapeutics Presents Positive Early Results from its Phase 1 Trial of Allogeneic CAR-T P-BCMA-ALLO1 in Relapsed-Refractory Multiple Myeloma at the 65th American Society of Hematology (ASH) Annual Meeting
Published: 2023-12-10 (Crawled : 20:20) - prnewswire.com
PSTX | $2.14 -11.93% 790K twitter stocktwits trandingview |
Health Technology
 | Email alert Add to watchlist
positive meeting car-t trial therapeutics results
Molecular Partners Presents Positive Initial Data from First Four Dosing Cohorts of Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at ASH Annual Meeting
Published: 2023-12-10 (Crawled : 20:20) - globenewswire.com
MOLN | $3.95 1.9K twitter stocktwits trandingview |
Professional, Scientific, and T...
 | Email alert Add to watchlist
mp0533 first positive ongoing aml meeting trial molecular
Cogent Biosciences Announces Positive Initial Data from Phase 2 SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis (NonAdvSM)
Published: 2023-12-09 (Crawled : 20:20) - globenewswire.com
COGT | $6.445 -0.85% 110K twitter stocktwits trandingview |
Health Technology
 | Email alert Add to watchlist
bezuclastinib positive trial
Ionis shares positive clinical update from ongoing trial of ION582 for Angelman syndrome
Published: 2023-11-11 (Crawled : 20:20) - prnewswire.com
IONS | $41.86 0.75% 90K twitter stocktwits trandingview |
Health Technology
 | Email alert Add to watchlist
ion582 positive update ongoing trial
Celldex Therapeutics Presents Positive Data from Prurigo Nodularis Phase 1b Study Demonstrating Meaningful Reduction in Itch and Skin Clearing with Single Dose 3.0 mg/kg Barzolvolimab
Published: 2023-11-05 (Crawled : 20:20) - globenewswire.com
CLDX | $39.01 -0.15% 27K twitter stocktwits trandingview |
Health Technology
 | | O: 26.94% H: 1.73% C: -11.01%
positive skin therapeutics study
Cogent Biosciences Announces Positive Lead-In Data from Ongoing Phase 3 PEAK Trial Evaluating Bezuclastinib in Combination with Sunitinib in Patients with Gastrointestinal Stromal Tumors (GIST)
Published: 2023-06-03 (Crawled : 20:20) - globenewswire.com
COGT | $6.445 -0.85% 110K twitter stocktwits trandingview |
Health Technology
 | Email alert Add to watchlist
bezuclastinib tumors positive ongoing gastrointestinal trial
Immix Biopharma Announces Positive NXC-201 Clinical Results at ASGCT: 100% Overall Response Rate in DARZALEX-Relapsed/Refractory AL Amyloidosis with Zero ICANs in Ongoing NEXICART-1 Phase 1b/2a Clinical Trial
Published: 2023-05-21 (Crawled : 20:20) - globenewswire.com
IMMX | $2.62 -1.5% 26K twitter stocktwits trandingview |
| | O: 17.68% H: 0.0% C: -9.33%
nxc-201 positive biopharma ongoing trial response results
Pliant Therapeutics Announces Positive Long-Term Data from the INTEGRIS-IPF Phase 2a Trial Demonstrating Bexotegrast was Well Tolerated at 320 mg with Durable Improvement Shown in FVC and Across Multiple Measures
Published: 2023-04-30 (Crawled : 20:20) - globenewswire.com
PLRX | $13.45 -0.74% 18K twitter stocktwits trandingview |
Health Technology
 | | O: -15.04% H: 0.0% C: -7.04%
positive bexotegrast trial therapeutics
Pliant Therapeutics Announces Positive Data from the INTEGRIS-IPF Phase 2a Trial Demonstrating Bexotegrast 320 mg was Well Tolerated and Achieved Statistically Significant FVC Increase in Patients with Idiopathic Pulmonary Fibrosis
Published: 2023-01-22 (Crawled : 20:20) - globenewswire.com
PLRX | $13.45 -0.74% 18K twitter stocktwits trandingview |
Health Technology
 | | O: 55.66% H: 4.17% C: -13.58%
fibrosis trial therapeutics positive phase 2b
Ionis presents positive Phase 2 data from open label extension study of donidalorsen at 2022 ACAAI Annual Meeting
Published: 2022-11-13 (Crawled : 20:20) - prnewswire.com
IONS | $41.86 0.75% 90K twitter stocktwits trandingview |
Health Technology
 | | O: 0.35% H: 4.08% C: 1.47%
label meeting extension positive study phase 2
Viridian Presents Positive Clinical Data from Ongoing VRDN-001 Phase 1/2 Trial in Active Thyroid Eye Disease (TED) Patients During Late-Breaking Presentations at the American Thyroid Association (ATA) 91st Annual Meeting
Published: 2022-10-22 (Crawled : 20:20) - globenewswire.com
VRDN | $15.4 -1.54% 57K twitter stocktwits trandingview |
Health Care and Social Assistan...
 | Email alert Add to watchlist
vrdn-001 ongoing thyroid disease active meeting eye trial positive
Plus Therapeutics Presents Positive Data from Ongoing ReSPECT™ Clinical Trials at the Annual Conference on CNS Clinical Trials and Brain Metastases
Published: 2022-08-13 (Crawled : 20:20) - globenewswire.com
PSTV | $1.74 3.8K twitter stocktwits trandingview |
Health Technology
 | Email alert Add to watchlist
ongoing trials conference therapeutics plus positive train brain metastases
Positive Phase 1 Data from mRNA-based Individualized Neoantigen Specific Immunotherapy in Patients with Resected Pancreatic Cancer presented at ASCO
Published: 2022-06-05 (Crawled : 20:20) - globenewswire.com
SNYNF | $92.966 630 twitter stocktwits trandingview |
Health Technology
 | Email alert Add to watchlist
SNY | $45.99 0.13% 70K twitter stocktwits trandingview |
Health Technology
 | Email alert Add to watchlist
BNTX | $86.525 -1.55% 320K twitter stocktwits trandingview |
Health Technology
 | Email alert Add to watchlist
immunotherapy asco positive cancer pancreatic phase 1
Vera Therapeutics Reports Positive Interim Phase 2 Data Showing MAU868 Has Significant BK Antiviral Activity in Kidney Transplant Patients
Published: 2022-06-04 (Crawled : 20:20) - globenewswire.com
VERA | $46.57 -2.92% 41K twitter stocktwits trandingview |
Professional, Scientific, and T...
 | Email alert Add to watchlist
mau868 antiviral kidney therapeutics positive phase 2
Avillion announces publication of positive full results from MANDALA Phase III trial of AstraZeneca's PT027 in asthma patients in the New England Journal of Medicine
Published: 2022-05-15 (Crawled : 20:20) - prnewswire.com
RPRX 4 | $27.665 -2.07% 390K twitter stocktwits trandingview |
Health Technology
 | Email alert Add to watchlist
pt027 trial positive results publication
Rezolute Announces Positive Data from its Phase 2b (RIZE) Study of RZ358 in Patients with Congenital Hyperinsulinism
Published: 2022-05-01 (Crawled : 20:20) - globenewswire.com
RZLT 4 | $3.615 17.37% 240K twitter stocktwits trandingview |
Technology Services
 | | O: 6.72% H: 2.1% C: 1.05%
rz358 positive phase 2b
REGENXBIO Presents Positive Interim Data from Phase II ALTITUDE™ Trial of RGX-314 for the Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery
Published: 2022-02-12 (Crawled : 20:20) - prnewswire.com
RGNX | $18.09 0.39% 13K twitter stocktwits trandingview |
Health Technology
 | Email alert Add to watchlist
CLSD | $1.29 64K twitter stocktwits trandingview |
Health Technology
 | Email alert Add to watchlist
rgx-314 treatment liver trial positive diabetic diabetes
Syndax Pharmaceuticals Announces Updated Positive Data Demonstrating Broad Activity and Tolerability of Axatilimab in Patients with Chronic Graft-Versus-Host Disease
Published: 2021-12-11 (Crawled : 20:20) - prnewswire.com
SNDX | $21.64 -0.37% 28K twitter stocktwits trandingview |
Health Technology
 | Email alert Add to watchlist
disease positive
Bavarian Nordic Reports Positive Topline Phase 2 Results for its COVID-19 Vaccine Candidate
Published: 2021-12-05 (Crawled : 20:20) - globenewswire.com
JNJ | $144.84 -1.86% 3M twitter stocktwits trandingview |
Health Technology
 | Email alert Add to watchlist
phase 2 covid positive phase 2 results results topline vaccine covid-19
Gainers vs Losers
49% 51%

Top 10 Gainers
TPET | $0.4801 107.75% 16M twitter stocktwits trandingview |
n/a
JAGX | $0.23 93.6% 310M twitter stocktwits trandingview |
Health Technology
WISA 4 | $3.17 81.14% 36M twitter stocktwits trandingview |
Electronic Technology
PALI | $6.57 57.93% 19M twitter stocktwits trandingview |
Manufacturing
BTTR | $7.61 49.22% 1.8M twitter stocktwits trandingview |
Manufacturing
PRSO | $1.79 40.95% 38M twitter stocktwits trandingview |
Manufacturing
DYNT | $0.5203 40.47% 17M twitter stocktwits trandingview |
Health Technology
MCBC | $13.755 38.52% 620K twitter stocktwits trandingview |
Finance
SNGX | $0.51 32.09% 6.3M twitter stocktwits trandingview |
Health Technology
SPCB | $0.364 31.88% 24M twitter stocktwits trandingview |
Electronic Technology
Your saved searches
Save your searches and get alerts when important news are released.